18:19 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Arvinas raises $120M in IPO

Arvinas Inc. (NASDAQ:ARVN) raised $120 million late Sept. 26 through the sale of 7.5 million shares at $16 in its bumped-up IPO. The price, at the top of its proposed $14-$16 range, values the company...
15:34 , Sep 27, 2018 |  BC Extra  |  Financial News

Trio of IPOs price: Arvinas, Sutro, Urovant

Arvinas Inc. (NASDAQ:ARVN), Sutro Biopharma Inc. (NASDAQ:STRO) and Urovant Sciences Ltd. (NASDAQ:UROV) each priced IPOs late Wednesday, raising a total of $345 million. On Thursday, Arvinas gained $0.05 to $16, and Sutro was up $0.20 to...
18:56 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
18:31 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on its...
19:59 , Aug 30, 2018 |  BC Extra  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on its...
21:36 , Aug 23, 2018 |  BC Extra  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
17:49 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies identified a benzopyran-based dual ESR1/ESR2 inhibitor and selective estrogen receptor down-regulator (SERD) that could help treat hormone therapy-resistant breast cancer. Chemical synthesis and testing in cell-based assays of...
15:14 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Roche scraps taselisib plans based on ASCO data

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said they will not seek approval for taselisib after the Phase III SANDPIPER study to treat metastatic breast cancer showed that the molecule provided limited benefit. However,...
12:28 , Jun 2, 2018 |  BC Extra  |  Clinical News

Roche scraps taselisib plans based on ASCO data

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said they will not seek approval for taselisib after the Phase III SANDPIPER study to treat metastatic breast cancer showed that the molecule provided limited benefit. However,...